Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $15.50

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has earned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $15.50.

Several research firms have recently weighed in on BCRX. Evercore ISI lifted their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. JMP Securities reissued a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Needham & Company LLC raised their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Barclays boosted their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th.

BioCryst Pharmaceuticals Trading Up 0.3 %

Shares of BCRX stock opened at $9.39 on Monday. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $9.48. The stock has a market cap of $1.94 billion, a P/E ratio of -15.39 and a beta of 1.75. The stock has a 50 day moving average of $7.94 and a 200 day moving average of $7.81.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of hedge funds have recently made changes to their positions in BCRX. GF Fund Management CO. LTD. purchased a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth approximately $33,000. Venturi Wealth Management LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth $46,000. R Squared Ltd acquired a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at about $48,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,322 shares in the last quarter. Finally, KBC Group NV lifted its stake in shares of BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after buying an additional 4,537 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.